PYC Therapeutics Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PYC.AX | PTCT | LYCA | SRPT | IDYA | 4591.T | |
|---|---|---|---|---|---|---|
| Market cap | 1.90B | 5.76B | 1.51B | 2.01B | 3.12B | 3.39B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -23.0 | 28.4 | — | 7.8 | -7.9 | -1.1 |
| Price/book | 2.7 | -30.1 | -3.2 | 1.3 | 2.9 | 1.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +58.80% | −5.09% | −3.60% | +7.65% | +8.41% | −29.21% |
| Today | +4.32% | +1.25% | +4.78% | +2.43% | +3.29% | −4.76% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All PYC.AX news ›PYC Therapeutics Falls More Than 10 Percent to $2.14 Ahead of Kidney Disease Data Presentation
PYC Therapeutics shares fell 10.46% ahead of a conference presentation on preliminary PYC-003 data, despite no new clinical results being released on Tuesday. SYDNEY â Shares of PYC Therapeutics fell more than 10 percent on Tuesday,…
Why Did PYC Therapeutics Fall So Sharply (ASX:PYC)?
Biotechnology stocks rarely need a reason to move, but a decline of this size on a day when the company released nothing does invite questions. The leading explanation is a broad retreat from speculative, long-dated growth stories as…
PYC Therapeutics Shares Lag The ASX 200 Today: The Latest
From a technical perspective, today’s sell-off points to a short term shift in momentum. PYC shares broke below both the 30 day and 50 day SMAs in the session, alongside the A$2.20 price level that had served as both resistance during the…
PYC Therapeutics Shares Slide Nearly 8% as Biotech Gives Back Gains Ahead of Key Kidney Disease Data
SYDNEY — Shares of PYC Therapeutics fell nearly 8% on Wednesday, erasing the previous session's gains as the Perth-based RNA drug developer's volatile run continued ahead of an important clinical data readout for its experimental kidney…
PYC Therapeutics Shares Jump 5% as Investors Bet on Kidney Disease Data From RNA Drug Developer This Year
SYDNEY — Shares of PYC Therapeutics rose more than 5% on Tuesday, extending a strong run for the Perth-based RNA drug developer as investors position ahead of a key data readout for its experimental treatment for an inherited kidney…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- ibtimes.com.au3
- kalkinemedia.com1
- thebull.com.au1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.